Photo Credit: Courtesy of Prostock-Studio/Shutterstock Jade Smith, Noelle Garbaccio, Samuel Lin, MD, FACS Facial fillers are undergoing their most dramatic aesthetic shift since their debut in the 1980s. In 1981, collagen derived from cows became the first cosmetic injection approved by the US FDA. In 2003, Restylane was introduced as the first hyaluronic acid (HA) filler, followed by approval of the first non-HA cosmetic filler, Radiesse (calcium hydroxylapetite), in 2006.
The filler market continues to expand. In the past five years, dermal filler procedures have more than doubled their annual numbers. The ASPS Statistics Report 2023 reported 6.
2 million hyaluronic acid (HA) and non-HA filler procedures in the year 2023 – that’s 17,000 fillers per day . No singular demographic is driving this trend; the percentage of total procedures by age group has been stable since 2018. While procedural numbers skyrocket, use by each age group grows at about the same rate.
One of the newest injectables, Juvederm Volux XC, may signify a shift in consumer interest. Fillers were traditionally used as soft tissue replacement, adding volume and smoothing wrinkles where age had hollowed the face. Juvederm Volux XC ushers in a new era, trading round cheeks and soft youth for sharp angles and chiseled contour.
Thicker than most fillers and the first HA filler indicated for the jawline and chin, Juvederm Volux XC may mimic bone instead of fat. This builds definition and takes advantage of pr.